Pharmacodynamic study on the muscle relaxation effect of rocuronium in patients with Parkinson's disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100053740

Enrollment

Unknown

Registered

2021-11-28

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Case series:No

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 65 years; 2. BMI <= 30 kg/m2; 3. ASA classification I-III.

Exclusion criteria

Exclusion criteria: 1. Have a history of neuromuscular disease or endocrine disease; 2. Electrolyte and acid-base balance disorders; 3. Arrhythmia; 4. Difficult airway; 5. Abnormal liver and kidney function; 6. Recently taking drugs that affect the function of the neuromuscular junction.

Design outcomes

Primary

Measure	Time frame
Plasma rocuronium concentration;Onset time of rocuronium;Peak time of rocuronium;25% recovery time;Recovery index;90% recovery time;	—

Countries

China

Contacts

Public ContactYang Chengwei

The First Affiliated Hospital of University of Science and Technology of China

yangcw1108@ustc.edu.cn+86 13013031356

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026